Six agentic solutions built natively inside ServiceNow address transaction processing, cross-cutting controls, and book-level remediation across the life and annuity operations lifecycle

CHICAGO, July 30, 2026 /PRNewswire/ — Plutus, the insurance AI company building the industry’s first insurance-native agentic platform, today announced the launch of the Plutus Agentic Platform for Life and Annuity Operations. The platform delivers six purpose-built agentic solutions organized around the way life and annuity operations actually work — transaction workflows, cross-cutting controls, and book-level remediation — all running natively inside ServiceNow and powered by Plutus Atlas, the company’s insurance-native semantic layer.

“We saw firsthand at ServiceNow how insurance leaders were drowning in AI noise,” said Kara Anderson, Co-Founder of Plutus. “There is no shortage of tools and certainly no shortage of demos, but nothing that was purpose-built for the complexity of life and annuity operations. We spent years watching carriers modernize workflows with ServiceNow but start to really hit a ceiling. Plutus Atlas is what brings the insurance-specific domain intelligence and layers it on top — and that is really why Plutus is so unique.”

The Problem the Platform Solves

Life and annuity operations face a structural challenge that point solutions cannot address. A not-in-good-order condition does not belong to any one transaction — it surfaces on a withdrawal, a distribution, and a beneficiary change simultaneously. Quality control runs across the entire book. Orphaned policies accumulate quietly and surface as escheatment and unclaimed property exposure. Fixing these problems one process at a time does not scale.

Most automation programs pick one lane. Automate the transaction and exceptions still land in a human queue. Automate exceptions without owning the workflow and the result is a smarter inbox, not a transformed operation. The Plutus Agentic Platform for Life and Annuity Operations addresses all three layers simultaneously.

At the core of every solution is Plutus Atlas, the insurance-native semantic layer that understands the relationships between policies, participants, products, and financial obligations across the fragmented systems that life and annuity carriers operate on. Plutus Atlas creates one version of policy, one version of customer, and one shared understanding of what a specific product means across every system that touches it — giving every agent the context it needs to execute accurately rather than guess.

The Six Solutions

Transaction Workflows

Money Out Distribution Agentic Assist captures distribution requests through participant self-service intake and orchestrates approvals, dependencies, and linked processes end to end. Flight checks complete before anything moves to core systems. The solution delivers 70% less manual casework, 3x faster case cycle time, 90% straight-through processing, 60% fewer NIGO delays, and funds disbursed in under five days.

Money Out Withdrawal Agentic Assist analyzes hardship events, validates documentation against IRS hardship standards, checks plan provisions and compliance obligations, and prepares audit-ready approval packages for faster, cleaner decisions. The solution delivers 75% less manual review, 3x faster case resolution, 90% straight-through approvals, 100% audit-ready case files, and funds disbursed in under 48 hours.

Loan Payout Agentic Assist takes participants from guided self-service intake through eligibility validation, compliance documentation, AI document validation, intelligent loan calculation, and express ACH disbursement — compressing weeks of loan processing into days. The solution delivers 5x faster loan payouts, funds via ACH in under 48 hours, 90% straight-through processing, 80% less manual review, and 70% fewer document errors.

Cross-Cutting Controls

NIGO Agentic Assist reviews forms, attachments, and signatures the moment work is created. Missing fields, bad data, and absent signatures are flagged instantly. Deficiency cases are created automatically, outreach is prepared, and validation reruns the moment new information arrives. Built for insurers scaling high-volume documents across life and annuities carriers, the solution delivers 40% faster cycle time, 10x cost avoided by minimizing NIGO, 60% reduced manual processing, 30% fewer intake errors, and 90% or greater accuracy in intelligence.

Quality Check Agentic Assist continuously scores every case for risk, complexity, and failure patterns. The right checks are scoped dynamically, the right reviewer is assigned by expertise, and guidance surfaces before downstream errors happen — replacing reactive blanket sampling with proactive risk-based quality. The solution delivers 60% fewer downstream errors, 3x faster risk detection, 50% less blanket QA volume, 80% of QA effort risk-targeted, and 40% higher reviewer throughput.

Book-Level Remediation

Orphaned Policy Agentic Assist continuously scans in-force policies for agent-status changes that leave them orphaned, predicts lapse risk and upsell potential for every account, and matches each policy to the right human agent through next-best-action routing — turning neglected accounts into active opportunities before they become escheatment exposure. The solution delivers results across a book where 40% of in-force policies are at risk of being orphaned, re-engaging over $100 million in policy value, reducing policy lapse rate by 25%, increasing upsell conversions by 30%, and reaching first outreach in under 24 hours.

Platform-Wide Impact

Across the six solutions, the Plutus Agentic Platform for Life and Annuity Operations delivers 80% less manual case review, 5x faster processing, 90% straight-through processing, 100% audit-ready case files, and over $100 million in at-risk policy value re-engaged.

Availability

The Plutus Agentic Platform for Life and Annuity Operations is available now for pilot deployments in the ServiceNow ecosystem. Money Out Distribution, Money Out Withdrawal, Loan Payout, NIGO Agentic Assist, Quality Check Agentic Assist, and Orphaned Policy Agentic Assist are ready for deployment. Beneficiary Change Agentic Assist and New Business Agentic Assist are currently in development. Organizations interested in a demonstration or pilot deployment can contact Plutus at plutustech.io.

About Plutus

Plutus is the insurance AI company building the industry’s first insurance-native agentic platform. At the foundation of every Plutus solution is Plutus Atlas, a semantic layer and ontology built specifically for insurance that gives AI agents the contextual understanding they need to reason accurately across fragmented systems and data sources. The Plutus Agentic Platform serves life and annuity carriers, P&C carriers, and commercial brokerages with purpose-built solutions across underwriting, operations, servicing, and distribution. Plutus is backed by ServiceNow Ventures and Moneta. Learn more at plutustech.io.

hello@plutustech.io

View original content to download multimedia:https://www.prnewswire.com/news-releases/plutus-launches-agentic-platform-for-life-and-annuity-operations-bringing-purpose-built-ai-to-the-workflows-that-define-service-quality-for-life-and-annuity-carriers-302839578.html

SOURCE Plutus Technology Solutions Inc.

SALT LAKE CITY, July 30, 2026 /PRNewswire/ — Zions Bancorporation, N.A. (NASDAQ: ZION) announced today that its board of directors has authorized share repurchases of up to $75 million of the company’s common stock for the third quarter of 2026 as part of the company’s previously authorized share repurchase target for 2026 of $300 million. The timing and amounts of any such actions will depend on market conditions, regulatory requirements, and other factors or uncertainties and may be updated at the discretion of the board.

The board also declared a regular quarterly dividend of $0.48 per common share, payable August 20, 2026, to shareholders of record at the close of business on August 13, 2026. The dividend represents a $0.03, or 6.7%, increase from the prior quarter.

Additionally, the board declared the regular quarterly cash dividend on the company’s Series A perpetual preferred shares (NASDAQ: ZIONP; CUSIP: 98973A104). The cash dividends on the preferred shares are payable September 15, 2026, to shareholders of record on September 1, 2026.

Zions Bancorporation, N.A. is one of the nation’s premier financial services companies with approximately $89 billion of total assets at December 31, 2025, and annual net revenue of $3.4 billion in 2025. Zions operates under local management teams and distinct brands in 11 western states: Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The Bank is a consistent recipient of national and state-wide customer survey awards in small- and middle-market banking, as well as a leader in public finance advisory services and Small Business Administration lending. In addition, Zions is included in the S&P MidCap 400 and NASDAQ Financial 100 indices. Investor information and links to local banking brands can be accessed at www.zionsbancorporation.com.  

View original content to download multimedia:https://www.prnewswire.com/news-releases/zions-bancorporations-board-announces-approval-of-share-repurchase-and-declares-dividends-on-common-and-preferred-stock-302839563.html

SOURCE Zions Bancorporation

With approximately €499,000 from the EIC Pre-Accelerator, Alchemi® is being developed to connect laboratory measurements, multi-country clinical data and healthcare workflows, supporting secure, interoperable deployment across distributed laboratories.

TORRES VEDRAS, Portugal, July 30, 2026 /PRNewswire/ — Proteotype Diagnostics Unipessoal LDA (“Proteotype”) today unveiled Alchemi®, its proprietary data and clinical workflow platform being developed for Enlighten®, the company’s investigational blood-based multi-cancer test.

Enlighten® measures changes in the body’s response to tumour development using a laboratory kit. Alchemi® is designed to standardise those measurements, govern analytical and machine-learning workflows and generate traceable, clinician-facing outputs. By supporting interoperability across laboratory and health-record systems through standards including HL7 FHIR and SNOMED CT, Alchemi® is intended to reduce reliance on a single central testing facility and make Enlighten® easier to integrate into local care pathways.

Proteotype’s MODERNISED and INNOVATOR studies are expanding the clinical evidence supporting Enlighten®. Alchemi® is intended to provide shared digital infrastructure through which multi-country datasets can be securely governed, analysed and translated into future clinical workflows.

Alchemi® will combine secure harmonisation of pseudonymised data generated across countries and laboratory environments; controlled development and validation of explainable machine-learning models; regulatory-compliant traceability; and a multilingual clinician portal for test ordering, result viewing and workflow management.

Its models are being designed to provide interpretable outputs, uncertainty measures and traceability of the data, model version and processing steps used to generate each result. A modular architecture will support jurisdiction-appropriate cloud deployment, with encryption, controlled access and comprehensive audit trails.

The 15-month development programme begins on 1 September 2026 and is supported by approximately €499,000 from the European Innovation Council’s Pre-Accelerator. The grant will support machine-learning optimisation, multi-country data harmonisation, clinician-interface development, interoperability, cloud security, and medical-device and software lifecycle, quality and technical documentation.

Proteotype was among 70 deep-tech companies selected from 22 countries under the EIC Pre-Accelerator call, which awarded approximately €32.5 million in total funding.

Wesley Sukdao, CEO and Co-Founder of Proteotype Diagnostics, said:

“Until now, we have spoken mainly about the biology and clinical studies behind Enlighten®. Alchemi® reveals the other half of the product: the secure data and software infrastructure required to turn laboratory measurements into reliable clinician-facing results. As our evidence base grows across cancers, countries and care settings, Alchemi® will help us manage that complexity while keeping Enlighten® scalable and accessible”

Dr Emma Yates, Chief Scientific Officer and Co-Founder, said:

“A diagnostic platform must do more than apply a machine-learning model. It must preserve the quality and traceability of every dataset, account for differences between populations and laboratory environments, and make clear how outputs are generated. Alchemi® is being built to provide that controlled, explainable and reproducible foundation for Enlighten®.”

Professor Gonçalo Bernardes, Co-Founder and Chair of Proteotype’s Scientific Advisory Board, said:

“Enlighten® combines a distinctive biological signal with laboratory technology and machine learning. Alchemi® brings those elements together as an integrated system, creating the infrastructure needed to translate scientific discovery into a clinically deployable and scalable diagnostic platform.”

Development will be led from Proteotype’s Torres Vedras site, where the company is recruiting for full-time roles in software engineering, data engineering, cybersecurity and healthcare integration.

About Proteotype Diagnostics

Proteotype is a pioneering diagnostics company dedicated to the development of advanced multi-cancer early detection and personalised medicine tests that measure the host response to tumour development. Its lead product, Enlighten®, is being evaluated as an accessible and scalable multi-cancer test designed to support earlier investigation and better-informed clinical decision-making.

Media contact: pr@proteotype.com
Career opportunities: https://proteotype.com/careers
General enquiries: support@proteotype.com

Funded by the European Union.

View original content to download multimedia:https://www.prnewswire.com/news-releases/proteotype-unveils-alchemi-the-data-and-orchestration-platform-behind-enlighten-302839577.html

SOURCE Proteotype Diagnostics